<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H08F225E88C654B5E8748C93F0D95C96E" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5803 IH: Saving American Families through Efficacy and Trusted Ways Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5803</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180515">May 15, 2018</action-date><action-desc><sponsor name-id="G000410">Mr. Gene Green of Texas</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human
			 Services to consider the potential for misuse and abuse when determining
			 whether to approve certain drugs, and for other purposes.</official-title></form>
	<legis-body id="HE3BE36E226BC4940BC395EA74B5A32CA" style="OLC">
 <section id="HFBF09FC621D947E9BC8F7BB06B26D7E0" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Saving American Families through Efficacy and Trusted Ways Act of 2018</short-title></quote> or the <quote><short-title>SAFETY Act of 2018</short-title></quote>.</text> </section><section id="H322717D351E64A728E45C06E3DE2FC31"><enum>2.</enum><header>Consideration of potential for misuse and abuse required for drug approval</header> <subsection id="H92DE89E9FC1F4E14BFB0F7701B216F3F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 505(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(d)</external-xref>) is amended—</text>
 <paragraph id="HCEB5E44BD2FE44C4B042C06100B9CDC6"><enum>(1)</enum><text display-inline="yes-display-inline">in the first sentence—</text> <subparagraph id="H51E0D69F5DBF46FEA64F6D64CC5F746E"><enum>(A)</enum><text>by striking <quote>or (7)</quote> and inserting <quote>(7)</quote>; and</text>
 </subparagraph><subparagraph id="H05CFAF7E5B9349D3BDBC313B476B6EA6"><enum>(B)</enum><text>by inserting <quote>; or (8) if the drug is or contains a controlled substance for which a listing in any schedule is in effect under the Controlled Substances Act or that is permanently scheduled pursuant to section 201 of such Act, on the basis of information submitted to him as part of the application, or upon the basis of any other information before him with respect to such drug, the drug is unsafe for use due to the risks of abuse or misuse or there is insufficient information to show that the drug is safe for use considering such risks;</quote> before <quote>he shall issue an order refusing to approve the application</quote>; and</text>
 </subparagraph></paragraph><paragraph id="HB7D51DA87BD64A54A3C4A9B570142A0D"><enum>(2)</enum><text>in the second sentence, by striking <quote>(6)</quote> and inserting <quote>(8)</quote>. <italic></italic></text> </paragraph></subsection><subsection id="HA2693A12E86440E787A9825FAF38618A"><enum>(b)</enum><header>Withdrawal authority</header><text display-inline="yes-display-inline">Section 505(e) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(e)</external-xref>) is amended in the first sentence—</text>
 <paragraph id="HB7BE52807CE44C4ABD8768C2F7EE1856"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>or (5)</quote> and inserting <quote>(5)</quote>; and</text> </paragraph><paragraph id="H4C7AFB44C17949DE9EB7BE7C730C1449"><enum>(2)</enum><text>by inserting the following: <quote>; or (6) that, in the case of a drug that is or contains a controlled substance for which a listing in any schedule is in effect under the Controlled Substances Act or that is permanently scheduled pursuant to section 201 of such Act, on the basis of new information before him with respect to such drug, evaluated together with the information available to him when the application was approved, that the drug is unsafe for use due to the risks of abuse or misuse</quote> after <quote>of a material fact</quote>.</text>
 </paragraph></subsection><subsection id="H0FF677A8937246AC8C6D2FA3C17E5ADF"><enum>(c)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in the amendments made by this section shall be construed to limit or narrow, in any manner, the meaning or application of the provisions of paragraphs (1), (2), (3), (4), (5), and (7) of section 505(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(d)</external-xref>) or paragraphs (1) and (2) of section 505(e) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(e)</external-xref>). <italic></italic></text>
			</subsection></section></legis-body></bill>


